Striatins and STRIPAK complex partners in clinical outcomes of patients with breast cancer and responses to drug treatment

• Published in: Chinese journal of cancer research 2023-08, Vol.35 (4), p.365-385
• Main Authors: Xinyu Li, Amber, Jianyuan Zeng, Jimmy, A Martin, Tracey, Ye, Lin, Ruge, Fiona, J Sanders, Andrew, Khan, Elyas, Ping Dou, Q., Davies, Eleri, G Jiang, Wen
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 1000-9604; 1993-0631
• DOI: 10.21147/j.issn.1000-9604.2023.04.04

ObjectiveStriatins (STRNs) family, which contains three multi-domain scaffolding proteins, are cornerstones of the striatins interacting phosphatase and kinase (STRIPAK) complex. Although the role of the STRIPAK complex in cancer has become recognized in recent years, its clinical significance in breast cancer has not been fully established. MethodsUsing a freshly frozen breast cancer tissue cohort containing both cancerous and adjacent normal mammary tissues, we quantitatively evaluated the transcript-level expression of all members within the STRIPAK complex along with some key interacting and regulatory proteins of STRNs. The expression profile of each molecule and the integrated pattern of the complex members were assessed against the clinical-pathological factors of the patients. The Cancer Genome Atlas (TCGA) dataset was used to evaluate the breast cancer patients' response to chemotherapies. Four human breast cancer cell lines, MDA-MB-231, MDA-MB-361, MCF-7, and SK-BR-3, were subsequently adopted for in vitro work. ResultsHere we found that high-level expressions of STRIP2, calmodulin, CCM3, MINK1 and SLMAP were respectively associated with shorter overall survival (OS) of patients. Although the similar pattern observed for STRN3, STRN4 and a contrary pattern observed for PPP2CA, PPP2CB and PPPR1A were not significant, the integrated expression profile of STRNs group and PPP2 group members constitutes a highly significant prognostic indicator for OS [P